Therapeutic strategies for Alzheimer's disease that aim to reduce levels of beta-amyloid have thus far come up empty-handed in the clinic. Now, two European teams have proposed contrasting strategies focused on hitting intermediate protein fragments and enzymatic steps in the pathway that produces amyloid.